IQVIA (IQV) FY2025 10-K Annual Report
IQVIA (IQV) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 17, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
IQVIA FY2025 10-K Analysis
Business Overview
- • Core business model: Global clinical development and commercial solutions services for biopharmaceutical industry
- • Emphasis on risks from client consolidation reducing service volumes and revenue loss post-mergers in clients’ industries
- • Increased focus on managing complex international regulatory, economic, and political risks impacting multi-country clinical trials
- • Workforce strategy: Leveraging global hiring in lower-cost countries to improve efficiency amid competition and wage inflation pressures
- • Noteworthy sustainability risk disclosure: Evolving global regulatory and stakeholder demands on sustainability could raise costs and reputational risks
Management Discussion & Analysis
- • Revenue $16,310M in 2025, up 5.9% (+$905M) YoY; Technology & Analytics Solutions +7.6% ($466M), Research & Development Solutions +4.3% ($369M), Contract Sales & Medical Solutions +9.7% ($70M)
- • Operating profit $2,182M in 2025, down 0.9% from $2,202M in 2024; segment profit: Technology & Analytics $1,595M (+4.8%), R&D $1,873M (-3.9%), Contract Sales $48M (+2.1%)
- • Best performing segment: Technology & Analytics Solutions revenue growth 7.6%, profit +4.8%; Worst performing segment: Research & Development Solutions profit decline by 3.9% despite revenue growth
- • Operating cash flow $2,654M; $1,714M net cash invested in acquisitions; cash and equivalents $1,980M (+$278M); $1,769M remaining stock repurchase authorization; total debt $15,800M, compliant with covenants
- • Management guidance: ongoing restructuring to streamline operations; expected continued integration of segments beginning 2026; risks from macroeconomic uncertainty, client cautiousness, and foreign currency fluctuations
Risk Factors
- • Regulatory risk: Compliance with HIPAA and EU GDPR, with potential fines and penalties under US Dept. of Health and Human Services and EU authorities
- • Geopolitical risk: Increased cyberattack threat from state-sponsored actors causing data compromise and operational disruption in global IT systems
- • Supply chain risk: Dependence on third-party suppliers for clinical trial materials and data; supplier restrictions or failures may materially harm operations
- • Competitive risk: Risk of lost or delayed large contracts due to clients shifting business to competitors or internal resources in biopharma services
- • Financial risk: Senior Secured Credit Facilities and note indentures restrict financing and operational flexibility, potentially limiting growth initiatives
IQVIA FY2025 Key Financial MetricsXBRL
Revenue
$16.3B
▲ +5.9% YoY
Net Income
$1.4B
▼ -0.9% YoY
Operating Margin
13.4%
▼ -92bp YoY
Net Margin
8.3%
▼ -57bp YoY
ROE
20.9%
▼ -172bp YoY
Total Assets
$29.9B
▲ +11.3% YoY
EPS (Diluted)
$7.84
▲ +4.7% YoY
Operating Cash Flow
$2.7B
▼ -2.3% YoY
Source: XBRL data from IQVIA FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on IQVIA
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.